U.S. Antifungal Drugs Market Summary
The U.S. antifungal drugs market was estimated at USD 6.05 billion in 2024 and is projected to reach USD 7.20 billion by 2030, growing at a CAGR of 3.0% from 2025 to 2030. The growing incidence of fungal infections drives market expansion.
Fungal infections cover a broad range of conditions, from athlete’s foot, ringworm, and vaginal yeast infections to severe systemic diseases such as candidemia, aspergillosis, and mucormycosis. The CDC identifies Candida auris and resistant Aspergillus species as serious threats, necessitating therapeutic advances and enhanced infection control. The U.S. antifungal drugs industry is mainly driven by a consistent increase in fungal infections among immunocompromised groups, such as cancer patients, transplant recipients, and individuals with HIV; a rise in ICU admissions; and the increased use of medical devices such as catheters and ventilators. This population is particularly vulnerable to invasive infections such as candidemia and aspergillosis, which require systemic antifungal treatments. Furthermore, superficial fungal infections such as onychomycosis and dermatophytosis remain widespread and frequently recur, maintaining steady demand for oral and topical antifungal medications. Surveillance data show that non-albicans Candida species cause approximately two-thirds of bloodstream infections, with 6% of isolates resistant to fluconazole and 2% of C. glabrata isolates resistant to echinocandins, highlighting the need for newer and more effective antifungal therapies.
Systemic fungal infections continue to pose a significant healthcare challenge in the U.S. Each year, more than 75,000 hospitalizations and nearly 9 million outpatient visits are attributed to fungal diseases, as per the CDC in May 2024. As per April 2024 data, ab out 25,000 cases of candidemia occur annually, with roughly one-third of patients dying during their hospital stay. Public health initiatives are steadily raising awareness of fungal diseases. The CDC’s Fungal Disease Awareness Week, scheduled for September 2025, aims to promote early diagnosis and enhance resistance surveillance.
U.S. Antifungal Drugs Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, the analyst has segmented the U.S. antifungal drugs market on the basis of drug class, indication, dosage form, and distribution channel:Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)
- Azoles
- Echinocandins
- Polyenes
- Allylamines
- Others
Indication Outlook (Revenue, USD Billion, 2018 - 2030)
- Dermatophytosis
- Aspergillosis
- Candidiasis
- Others
Dosage Form Outlook (Revenue, USD Billion, 2018 - 2030)
- Oral Drugs
- Ointments
- Powders
- Others
Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
- Hospital Pharmacies
- Retails Pharmacies
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Antifungal Drugs Market Variables, Trends & Scope
Chapter 4. U.S. Antifungal Drugs Market: Drug class Estimates & Trend Analysis
Chapter 5. U.S. Antifungal Drugs Market: Indication Estimates & Trend Analysis
Chapter 6. U.S. Antifungal Drugs Market: Dosage Form Estimates & Trend Analysis
Chapter 7. U.S. Antifungal Drugs Market: Distribution Channel Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Bayer AG
- Sanofi.
- Merck & Co., Inc.
- GSK plc.
- Abbott.
- GLENMARK PHARMACEUTICALS INC., USA
- Enzon Pharmaceuticals, Inc.
- Astellas Pharma US, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | July 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 6.05 Billion |
| Forecasted Market Value ( USD | $ 7.2 Billion |
| Compound Annual Growth Rate | 3.0% |
| Regions Covered | United States |
| No. of Companies Mentioned | 10 |
